HIGHLIGHTS
- who: TYPE and colleagues from the Affiliated Hospital of Weifang Medical University, China have published the research work: Exploring immune interactions in triple negative breast cancer: IL-1 inhibition and its therapeutic potential, in the Journal: (JOURNAL)
SUMMARY
Emerging research has demonstrated that patients with ER-low disease have clinical outcomes similar to patients with TNBC (Dieci et_al, 2021; Schrodi et_al, 2021), raising questions about current classifications systems and treatment paradigms for patients with ER-low disease. Novel therapies capable of modulating immunosuppressive TAMs (Schmid and Varner, 2010; Coussens et_al, 2013; Gajewski et_al . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.